NASDAQ:IMNN

Imunon Stock News

Healthcare > Biotechnology

Buy IMNN

*Your capital is at risk

$2.10

-0.0400 (-1.87%)

At Close: Jun 03, 2026

IMUNON Appoints Douglas V. Faller, M.D.

08:05am, Monday, 10'th Feb 2025

Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

08:05am, Thursday, 19'th Dec 2024

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable futur

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

08:05am, Tuesday, 10'th Dec 2024

Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) population of women newly diagnosed with advanced ovarian canc

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

08:05am, Monday, 25'th Nov 2024

FDA Project Team supports the company's proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

05:11pm, Thursday, 07'th Nov 2024

Imunon, Inc. (NASDAQ:IMNN ) Q3 2024 Earnings Conference Call November 7, 2024 11:00 AM ET Company Participants Kim Golodetz - Alliance Advisors IR Stacy Lindborg - President & Chief Executive Officer

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

10:00am, Thursday, 07'th Nov 2024

IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

08:05am, Thursday, 07'th Nov 2024

Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J.

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

08:30am, Thursday, 31'st Oct 2024

LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vacc

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

09:05am, Wednesday, 30'th Oct 2024

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptance Company also announces FDA End-of-Phase 2 in-person meeting to discuss Phase 3 trial of IMNN-001 Phase 3 trial is

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

08:05am, Monday, 07'th Oct 2024

LAWRENCEVILLE, N.J., Oct. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (the “Company”), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today an

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

04:06pm, Monday, 09'th Sep 2024

September 18 th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by